Arrowhead Pharmaceuticals (ARWR) SEC Filings & 10K Form

$23.01
-0.12 (-0.52%)
(As of 11:32 AM ET)

Recent Arrowhead Pharmaceuticals SEC Filings

DateFilerForm TypeView
04/10/2024
1:03 PM
Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
04/03/2024
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2024
3:30 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2024
6:06 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2024
3:38 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/18/2024
6:00 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/08/2024
4:54 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:30 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2024
4:25 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:57 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/26/2024
4:28 PM
Arrowhead Pharmaceuticals (Filer)
Form DEFA14A
01/24/2024
11:57 AM
Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
01/23/2024
3:14 PM
Arrowhead Pharmaceuticals (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
01/17/2024
5:32 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:22 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144/A
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2024
3:48 PM
Arrowhead Pharmaceuticals (Subject)
Vakiener Victoria (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/11/2024
3:38 PM
Arrowhead Pharmaceuticals (Subject)
Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/11/2024
3:22 PM
Arrowhead Pharmaceuticals (Subject)
Ferrari Mauro (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2024
4:16 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
4:16 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
4:17 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
6:58 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
7:02 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
4:33 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
4:14 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:39 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:21 PM
Arrowhead Pharmaceuticals (Subject)
San Martin Javier (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2024
3:08 PM
Arrowhead Pharmaceuticals (Subject)
Oliver Tracie (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
4:25 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
4:27 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2024
12:49 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
12:06 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
12:25 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
11:24 AM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2024
3:44 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2023
4:04 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/21/2023
3:34 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (Ad)

Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.

Click on Adam's shiny forehead for more details.
12/19/2023
2:51 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:52 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:54 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:55 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
2:41 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2023
4:16 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/29/2023
3:10 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/22/2023
1:31 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2023
5:23 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2023
4:51 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/28/2023
1:50 PM
Arrowhead Pharmaceuticals (Subject)
Vakiener Victoria (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/20/2023
5:10 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
3:20 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2023
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/05/2023
5:15 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2023
12:04 PM
Arrowhead Pharmaceuticals (Subject)
Oliver Tracie (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/30/2023
12:33 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2023
5:41 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2023
1:15 PM
Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
05/08/2023
5:29 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2023
6:04 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2023
1:36 PM
Arrowhead Pharmaceuticals (Subject)
GIVEN DOUGLAS B (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/03/2023
2:42 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:ARWR) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners